Home LiteratureArticle Details
PMID: 17453008 Published · ppublish English Journal Article Meta-Analysis

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.

British journal of cancer ·Vol. 96 ·No. 10 ·2007-05-21 ·Pages 1504-13

de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M

Abstract

The Ki-67 antigen is used to evaluate the proliferative activity of breast cancer (BC); however, Ki-67's role as a prognostic marker in BC is still undefined. In order to better define the prognostic value of Ki-67/MIB-1, we performed a meta-analysis of studies that evaluated the impact of Ki-67/MIB-1 on disease-free survival (DFS) and/or on overall survival (OS) in early BC. Sixty-eight studies were identified and 46 studies including 12 155 patients were evaluable for our meta-analysis; 38 studies were evaluable for the aggregation of results for DFS, and 35 studies for OS. Patients were considered to present positive tumours for the expression of Ki-67/MIB-1 according to the cut-off points defined by the authors. Ki-67/MIB-1 positivity is associated with higher probability of relapse in all patients (HR=1.93 (95% confidence interval (CI): 1.74-2.14); P<0.001), in node-negative patients (HR=2.31 (95% CI: 1.83-2.92); P<0.001) and in node-positive patients (HR=1.59 (95% CI: 1.35-1.87); P<0.001). Furthermore, Ki-67/MIB-1 positivity is associated with worse survival in all patients (HR=1.95 (95% CI: 1.70-2.24; P<0.001)), node-negative patients (HR=2.54 (95% CI: 1.65-3.91); P<0.001) and node-positive patients (HR=2.33 (95% CI: 1.83-2.95); P<0.001). Our meta-analysis suggests that Ki-67/MIB-1 positivity confers a higher risk of relapse and a worse survival in patients with early BC.

MeSH Terms
Biomarkers, Tumor/analysis,metabolism Breast Neoplasms/diagnosis,mortality,pathology,therapy Carcinoma/diagnosis,mortality,pathology,therapy Disease-Free Survival Female Follow-Up Studies Humans Ki-67 Antigen/analysis,metabolism Prognosis Survival Analysis
Chemicals
Biomarkers, Tumor Ki-67 Antigen
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
de Azambuja E
Medical Oncology Clinic, Jules Bordet Institute, 125 Boulevard de Waterloo, 1000, Brussels, Belgium.
Cardoso F
de Castro G
Colozza M
Mano M S
Durbecq V
Sotiriou C
Larsimont D
Piccart-Gebhart M J
Paesmans M
References (96)
96 references, click to expand
  1. Reporting recommendations for tumor marker prognostic studies.
    J Clin Oncol. 2005 Dec 20;23(36):9067-72 PMID: 16172462
  2. Standards for reporting prognostic tumor marker studies.
    J Clin Oncol. 2005 Dec 20;23(36):9053-4 PMID: 16301590
  3. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
    Clin Cancer Res. 2006 Jan 1;12(1):159-68 PMID: 16397038
  4. [Predictive variables of lymphatic metastasis in breast carcinoma with a diameter below 2 cm].
    Suppl Tumori. 2005 May-Jun;4(3):S172 PMID: 16437969
  5. Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer.
    Breast Cancer Res Treat. 1996;37(1):57-64 PMID: 8750528
  6. The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer.
    J Cancer Res Clin Oncol. 1996;122(11):687-92 PMID: 8898980
  7. MIB-1 proliferative activity in invasive breast cancer measured by image analysis.
    J Clin Pathol. 1996 Nov;49(11):926-30 PMID: 8944614
  8. Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer.
    Acta Oncol. 1997;36(4):369-74 PMID: 9247096
  9. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer.
    J Clin Oncol. 1999 Feb;17(2):470-7 PMID: 10080587
  10. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.
    Br J Cancer. 1999 May;80(3-4):419-26 PMID: 10408848
  11. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.
    Eur J Surg Oncol. 1999 Aug;25(4):356-63 PMID: 10419704
  12. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.
    Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7 PMID: 10430922
  13. Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases.
    Breast Cancer Res Treat. 1999 May;55(1):61-71 PMID: 10472780
  14. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
    N Engl J Med. 2004 Dec 30;351(27):2817-26 PMID: 15591335
  15. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
    Lancet. 2005 Feb 19-25;365(9460):671-9 PMID: 15721472
  16. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma.
    Tumori. 2005 Jan-Feb;91(1):46-52 PMID: 15850004
  17. ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer.
    Ann Oncol. 2005;16 Suppl 1:i7-9 PMID: 15888763
  18. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
    Lancet. 2005 May 14-20;365(9472):1687-717 PMID: 15894097
  19. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.
    J Clin Invest. 2005 Jun;115(6):1503-21 PMID: 15931389
  20. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density.
    Oncol Rep. 2005 Aug;14(2):425-31 PMID: 16012726
  21. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.
    Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5 PMID: 16141321
  22. Proliferation marker Ki-67 in early breast cancer.
    J Clin Oncol. 2005 Oct 1;23(28):7212-20 PMID: 16192605
  23. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
    Ann Oncol. 2005 Nov;16(11):1723-39 PMID: 15980158
  24. Prognostic and predictive factors revisited.
    Breast. 2005 Dec;14(6):493-9 PMID: 16239111
  25. Common markers of proliferation.
    Nat Rev Cancer. 2006 Feb;6(2):99-106 PMID: 16491069
  26. Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response.
    Int J Cancer. 2006 May 15;118(10):2609-16 PMID: 16381002
  27. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.
    J Clin Oncol. 2006 Apr 10;24(11):1656-64 PMID: 16505416
  28. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
    J Clin Oncol. 2006 Aug 10;24(23):3726-34 PMID: 16720680
  29. AgNORs in breast tumours.
    Micron. 2000 Apr;31(2):143-9 PMID: 10588060
  30. Bcl-2 immunostaining: a way to finding unresponsive postmenopausal N+ breast cancer patients.
    Anticancer Res. 2000 Mar-Apr;20(2B):1213-9 PMID: 10810424
  31. The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67.
    Breast Cancer Res Treat. 2000 Jan;59(2):113-23 PMID: 10817346
  32. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.
    Anticancer Res. 2000 May-Jun;20(3A):1451-61 PMID: 10928056
  33. Gene expression profiling predicts clinical outcome of breast cancer.
    Nature. 2002 Jan 31;415(6871):530-6 PMID: 11823860
  34. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment.
    Br J Cancer. 2002 Feb 1;86(3):402-8 PMID: 11875707
  35. Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer.
    Breast Cancer Res Treat. 2002 Jan;71(2):161-70 PMID: 11881912
  36. [Correlation of size of the primary tumor and axillary node status with the p53 tumor suppressor gene in carcinoma of the breast].
    Vojnosanit Pregl. 2002 Jan-Feb;59(1):29-32 PMID: 11928186
  37. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
    Cancer. 2002 Apr 15;94(8):2151-9 PMID: 12001111
  38. Vimentin expression does not assist in predicting survival in ductal carcinoma of the breast.
    Pathology. 2002 Jun;34(3):230-2 PMID: 12109782
  39. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
    Oncol Rep. 2003 Jan-Feb;10(1):121-5 PMID: 12469156
  40. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?
    Cancer. 2003 Mar 1;97(5):1321-31 PMID: 12599241
  41. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis.
    J Clin Pathol. 2003 Mar;56(3):214-20 PMID: 12610102
  42. Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma: prognostic significance.
    Cancer. 2003 Mar 15;97(6):1376-86 PMID: 12627500
  43. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Cancer. 2003 Mar 15;97(6):1573-81 PMID: 12627523
  44. Association between histology grade, expression of HsMCM2, and cyclin A in human invasive breast carcinomas.
    J Clin Pathol. 2003 May;56(5):368-73 PMID: 12719458
  45. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.
    J Clin Oncol. 2003 Sep 1;21(17):3357-65 PMID: 12847142
  46. Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer.
    J Clin Oncol. 2003 Dec 1;21(23):4306-13 PMID: 14645419
  47. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
    Cancer. 2004 Feb 1;100(3):499-506 PMID: 14745865
  48. Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival.
    Clin Cancer Res. 2004 Mar 15;10(6):2058-64 PMID: 15041726
  49. Prognostic value of different factors in breast carcinoma.
    Tumori. 2004 Jan-Feb;90(1):112-9 PMID: 15143983
  50. [The specificity of expression of molecular biological markers in tumors of the mammary gland].
    Vestn Ross Akad Med Nauk. 2004;(5):32-6 PMID: 15320547
  51. Meta-analyses based on abstracted data: a step in the right direction, but only a first step.
    J Clin Oncol. 2004 Oct 1;22(19):3839-41 PMID: 15326196
  52. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases.
    Anticancer Res. 2004 Sep-Oct;24(5B):3283-8 PMID: 15510624
  53. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.
    Int J Cancer. 1983 Jan 15;31(1):13-20 PMID: 6339421
  54. Beta blockade during and after myocardial infarction: an overview of the randomized trials.
    Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71 PMID: 2858114
  55. Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
    Br J Cancer. 1989 Jun;59(6):943-7 PMID: 2472168
  56. Ki-67 immunostaining in human breast tumors and its relationship to prognosis.
    Cancer. 1991 Jan 15;67(2):421-8 PMID: 1845945
  57. [In situ determination of the Ki-67 growth fraction (Ki-67 GF) in human tumors (studies in breast cancer)].
    Acta Histochem Suppl. 1990;39:109-24 PMID: 2080254
  58. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis.
    Cancer. 1991 Aug 1;68(3):549-57 PMID: 1648433
  59. Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67.
    Breast Cancer Res Treat. 1991 Aug;18(3):149-54 PMID: 1756257
  60. Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival.
    Eur J Surg Oncol. 1992 Jun;18(3):224-9 PMID: 1607032
  61. Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer.
    Br J Cancer. 1992 Nov;66(5):970-6 PMID: 1419645
  62. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.
    J Pathol. 1992 Dec;168(4):357-63 PMID: 1484317
  63. Meta-analysis of the literature or of individual patient data: is there a difference?
    Lancet. 1993 Feb 13;341(8842):418-22 PMID: 8094183
  64. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer.
    Br J Cancer. 1993 Sep;68(3):579-83 PMID: 8394732
  65. Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences.
    Eur J Cancer. 1993;29A(11):1509-13 PMID: 8217353
  66. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma.
    Breast Cancer Res Treat. 1994 Jan;29(1):59-71 PMID: 7912568
  67. Invited commentary: a critical look at some popular meta-analytic methods.
    Am J Epidemiol. 1994 Aug 1;140(3):290-6 PMID: 8030632
  68. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival.
    Br J Cancer. 1995 Jan;71(1):146-9 PMID: 7819031
  69. Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias?
    J Clin Epidemiol. 1995 Jan;48(1):159-63 PMID: 7853041
  70. Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis.
    Breast Cancer Res Treat. 1994;32(2):165-75 PMID: 7865846
  71. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.
    Gynecol Oncol. 1995 Apr;57(1):96-104 PMID: 7705708
  72. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1.
    Am J Clin Pathol. 1995 Jul;104(1):42-9 PMID: 7611179
  73. From science to practice. Meta-analyses using individual patient data are needed.
    JAMA. 1995 Sep 13;274(10):845-6 PMID: 7650811
  74. The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer.
    J Pathol. 1995 Aug;176(4):343-52 PMID: 7562249
  75. Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors.
    Cancer Detect Prev. 1995;19(5):446-50 PMID: 7585732
  76. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis.
    Int J Cancer. 1996 Apr 22;69(2):135-41 PMID: 8608982
  77. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer.
    Anticancer Res. 1995 Nov-Dec;15(6B):2717-22 PMID: 8669852
  78. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas.
    Breast Cancer Res Treat. 1996;37(2):101-13 PMID: 8750578
  79. Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma.
    Breast Cancer Res Treat. 1996;37(2):123-33 PMID: 8750580
  80. Language bias in randomised controlled trials published in English and German.
    Lancet. 1997 Aug 2;350(9074):326-9 PMID: 9251637
  81. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis.
    Int J Cancer. 1997 Aug 22;74(4):433-7 PMID: 9291434
  82. p53 expression is of independent predictive value in lymph node-negative breast carcinoma.
    Eur J Cancer. 1997 Jul;33(8):1268-74 PMID: 9301454
  83. Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis.
    J Pathol. 1998 Feb;184(2):130-5 PMID: 9602702
  84. Prognostic relevance of immunohistology, tumor size and vascular space involvement in axillary node negative breast cancer.
    Arch Gynecol Obstet. 1998;261(3):139-46 PMID: 9651658
  85. Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR.
    J Pathol. 1998 May;185(1):25-31 PMID: 9713356
  86. MIB-1 labelling index is an independent prognostic marker in primary breast cancer.
    Br J Cancer. 1998 Aug;78(4):460-5 PMID: 9716027
  87. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein.
    Clin Cancer Res. 1996 Jan;2(1):147-54 PMID: 9816101
  88. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer.
    Clin Cancer Res. 1996 Mar;2(3):585-92 PMID: 9816207
  89. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.
    Stat Med. 1998 Dec 30;17(24):2815-34 PMID: 9921604
  90. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer.
    J Natl Cancer Inst. 1999 Feb 3;91(3):271-8 PMID: 10037106
  91. Prognostic value of vascular density and cell proliferation in breast cancer patients.
    Pathol Res Pract. 1999;195(1):31-7 PMID: 10048092
  92. Low levels of cell cycle inhibitor p27kip1 combined with high levels of Ki-67 predict shortened disease-free survival in T1 and T2 invasive breast carcinomas.
    Int J Oncol. 2001 Jan;18(1):17-23 PMID: 11115534
  93. Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy.
    J Cancer Res Clin Oncol. 2000 Dec;126(12):722-9 PMID: 11153146
  94. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer.
    Clin Cancer Res. 2001 Jun;7(6):1716-23 PMID: 11410511
  95. Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma.
    J Clin Pathol. 2001 Jul;54(7):543-9 PMID: 11429427
  96. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.
    J Natl Cancer Inst. 2001 Jul 4;93(13):979-89 PMID: 11438563
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
DOI
10.1038/sj.bjc.6603756
Published
2007-05-21
Epub
2007-00-24
Pages
1504-13
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2359936
Subset
IM
External Links
PubMed source DOI: 10.1038/sj.bjc.6603756 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2